Early Detection - The best chance to reduce cancer mortality rate is through early detection and intervention.
Prof. Ebenstein ‘s lab studies a potential genetic biomarker for early detection of cancer. It has been shown that epigenetic modification 5-Hydroxymethylcytosine (5hmC), which is an oxidized form of DNA methylation is lost in a wide variety of cancers. Dr. Yael Michaeli and Dr. Shahar Zirkin are directing a Horizon 2020 funded team focusing on the utility of 5hmC as a biomarker for early diagnosis and response to therapy. Results from the lab have shown promise for the early detection of blood and colon cancers and two patents were submitted.
First results have been submitted for publication.
Prof. Yuval Ebenstein PhD
Faculty of Exact Sciences, School of Chemistry